Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-050310
Filing Date
2017-08-25
Accepted
2017-08-25 16:57:59
Documents
1
Period of Report
2017-08-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3125
  Complete submission text file 0001209191-17-050310.txt   4439
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE, SUITE 950 NASHVILLE TN 37203
Business Address
Bonner Michael (Reporting) CIK: 0001666790 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 171052547